USA - NASDAQ:ZY - US98985X1000 - Common Stock
The current stock price of ZY is 2.43 USD. In the past month the price decreased by -6.18%. In the past year, price decreased by -76.75%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| DOW | DOW INC | N/A | 16.25B | ||
| WLK | WESTLAKE CORP | N/A | 8.02B | ||
| CBT | CABOT CORP | 8.48 | 3.28B | ||
| HWKN | HAWKINS INC | 31.79 | 2.64B | ||
| OLN | OLIN CORP | 29.16 | 2.31B | ||
| PCT | PURECYCLE TECHNOLOGIES INC | N/A | 1.66B | ||
| MATV | MATIV HOLDINGS INC | 20.24 | 697.04M | ||
| WLKP | WESTLAKE CHEMICAL PARTNERS L | 13.24 | 653.35M | ||
| KOP | KOPPERS HOLDINGS INC | 6.94 | 570.70M | ||
| KRO | KRONOS WORLDWIDE INC | N/A | 544.19M | ||
| TROX | TRONOX HOLDINGS PLC | N/A | 534.21M | ||
| ASIX | ADVANSIX INC | 6.71 | 421.66M |
Zymergen, Inc. engages in the design, development, and commercialization of bio-based products. The company is headquartered in Emeryville, California and currently employs 507 full-time employees. The company went IPO on 2021-04-22. Its platform consists of three key capabilities: its collection of accessible biomolecules; its software and data science technology, and its data-driven microbe optimization processes. Its businesses include advanced materials, which seeks to employ bio-advantaged molecules or microbes to develop and deliver products and is focused on four markets: agriculture, water repellency, advanced polymers, and healthcare; drug discovery business leverages its differentiated access to natural products as a source of diverse chemical matter provided by its unified metagenomics database, and automation business, which offers automation technology to organizations involved in lab operations. Its software and data science platform informs, guides, and records its experiments forming the infrastructure for the learning cycle.
ZYMERGEN INC
5959 Horton Street, Suite 700
Emeryville CALIFORNIA US
Employees: 507
Phone: 14158018073.0
Zymergen, Inc. engages in the design, development, and commercialization of bio-based products. The company is headquartered in Emeryville, California and currently employs 507 full-time employees. The company went IPO on 2021-04-22. Its platform consists of three key capabilities: its collection of accessible biomolecules; its software and data science technology, and its data-driven microbe optimization processes. Its businesses include advanced materials, which seeks to employ bio-advantaged molecules or microbes to develop and deliver products and is focused on four markets: agriculture, water repellency, advanced polymers, and healthcare; drug discovery business leverages its differentiated access to natural products as a source of diverse chemical matter provided by its unified metagenomics database, and automation business, which offers automation technology to organizations involved in lab operations. Its software and data science platform informs, guides, and records its experiments forming the infrastructure for the learning cycle.
The current stock price of ZY is 2.43 USD. The price increased by 1.67% in the last trading session.
ZY does not pay a dividend.
ZY has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZY.
ZYMERGEN INC (ZY) has a market capitalization of 253.58M USD. This makes ZY a Micro Cap stock.
ChartMill assigns a technical rating of 1 / 10 to ZY. When comparing the yearly performance of all stocks, ZY is a bad performer in the overall market: 73.38% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to ZY. ZY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ZY reported a non-GAAP Earnings per Share(EPS) of -3.34. The EPS increased by 53.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -2508.94% | ||
| ROA | -77.49% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
11 analysts have analysed ZY and the average price target is 2.35 USD. This implies a price decrease of -3.46% is expected in the next year compared to the current price of 2.43.
For the next year, analysts expect an EPS growth of 33.88% and a revenue growth -21.93% for ZY